Ocugen Inc (OCGN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.06 (+2.91%), Market cap $0.49B, 52-week low–high $0.67 ~ $2.48.
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt
Financial statements, price targets, institutional (13F) holdings and related news for Ocugen Inc are updated in real time on BlackAll Trade.
Ocugen Inc trades at $1.06 (+2.91%). Real-time quotes and charts are available on BlackAll Trade.
Ocugen Inc has a market cap of about $0.49B.
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pi